Funding Details
- Awarder
- Inbox
- Date Award
- April 01, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Traction
- Airna estimates approximately 100,000 people in the U.S. have AATD, and the company is preparing to launch a Phase 1/2 trial for its lead program.
- Founders
- Thorsten Stafforst, Jin Billy Li
- Company Description
- Airna is a biotechnology startup developing RNA editing treatments, specifically targeting alpha-1 antitrypsin deficiency (AATD) by repairing faulty RNA to produce functional AAT protein, thereby reducing the risk of associated lung and liver diseases.
- Market
- RNA editing treatments for alpha-1 antitrypsin deficiency
- Location
-
USA
- Coinvestors
- Venrock, Forbion, RTW Investments, Arch Venture Partners, Nextech Invest
Links